Efficacy and safety of alogliptin added to insulin in Japanese patients with type
2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial
followed by an open-label, long-term extension phase.
Author(s): Kaku K(1), Mori M, Kanoo T, Katou M, Seino Y.
Affiliation(s): Author information:
(1)Kawasaki Medical School , 577, Matsushima, Kurashiki-shi, Okayama 701-0192 ,
Japan +81 86 462 1111 ; +81 86 462 1199 ; kka@med.kawasaki-m.ac.jp.
Publication date & source: 2014, Expert Opin Pharmacother. , 15(15):2121-30
OBJECTIVE: To evaluate the efficacy and safety of alogliptin added to insulin in
Japanese patients with type 2 diabetes mellitus (T2DM) who are poorly controlled
with insulin and diet or exercise.
STUDY DESIGN: This was a randomized, double-blind, 12-week comparative trial of
alogliptin and insulin versus placebo and insulin in 179 patients with T2DM
followed by a 40-week, open-label phase in 169 patients on alogliptin and
insulin.
PRIMARY OUTCOME MEASURE: Change in glycated hemoglobin (HbA1c) from baseline to
the end of double-blind phase (week 12).
RESULTS: The change in HbA1c (least squares means) from baseline to week 12 was
-0.96% for the alogliptin and insulin group and -0.29% for the placebo and
insulin group. The point estimate (95% confidence interval) intergroup difference
was -0.66% ([-0.824%, -0.503%]). In the alogliptin and insulin group, HbA1c
started to decrease from week 2 onward and peaked by week 12. The proportions of
patients who achieved HbA1c < 8.0, < 7.0 and < 6.0% at week 12 were significantly
higher in alogliptin and insulin group (73.0, 23.3 and 1.1%) than in placebo and
insulin group (25.0, 5.7 and 0%). Incidences of adverse effects were comparable
between groups, with no relevant increases in hypoglycemia or weight gain seen.
CONCLUSIONS: Alogliptin 25 mg/day was effective and well tolerated when added to
insulin in Japanese patients with inadequately controlled T2DM.
|